Several patient registries are available to track various data on cancer patients with COVID-19. Below is a listing of several options for your consideration.
American College of Surgeons COVID-19 Registry
The American College of Surgeons (ACS) has developed the ACS COVID-19 Registry, which is available to all hospitals seeking to capture meaningful data about the COVID-19 patients. This registry will collect data on COVID-19 patients who did not undergo surgery as well as COVID-19 patients who did. Included data variables cover demographics, severity predictors, admission information, hospitalization information, therapies used, and discharge information. Participating hospitals will be able to capture all patients ages 18 and older and tracked from hospital admission through discharge. More information is available at: https://www.facs.org/quality-programs/covid19-registry.
The American Society of Breast Surgeons COVID-19 Registry
The American Society of Breast Surgeons has developed a COVID-19 specific registry within the ASBrS Mastery of Breast Surgery Program℠. Mastery is a members-only HIPAA compliant program that can capture patient specific data. A new, short data entry process for patients treated during this COVID-19 era has been created. If you already participate in Mastery, you can continue to input your patient data as you have done and add a few COVID-19 specific questions for each patient and the data will be linked. More information is available at https://www.breastsurgeons.org/resources/covid19_registry.
American Society of Clinical Oncology COVID-19 in Oncology Registry
The ASCO Survey on COVID-19 in Oncology Registry (ASCO Registry) aims to address the urgent need from the cancer community to communicate about the pattern of symptoms and severity of COVID-19 among patients with cancer, as well as how COVID-19 infections impact the delivery of cancer care and patient outcomes. The ASCO Registry is designed to collect both baseline and follow-up data on how the virus impacts cancer care and cancer patient outcomes during the COVID-19 pandemic and into 2021. The registry is open to all U.S. oncology practices, including physician-owned, academic, and hospital/health system-owned practices, and hospitals (regardless of whether cancer specific). ASCO plans to make funding available to practices to help cover research data-entry costs. Initial submissions will result in a $1500 payment; additional payments will be based on the number of records a practice inputs into the registry. Learn more about the ASCO Registry by visiting: https://www.asco.org/asco-coronavirus-information/coronavirus-registry.
COVID-19 and Cancer Consortium (CCC19)
CCC19 is a consortium of over 100 cancer centers and other organizations, most of which are NCI-designated Comprehensive Cancer Centers or NCI-designated Cancer Centers. The main expectation is that the participating institution will make an effort to identify and report ALL cases of COVID-19 in patients with a current or prior history of invasive malignancy – not just those in the critically ill. In order to fully understand this pandemic, data on relatively asymptomatic outpatients as well as those heavily affected by the disease needs to be captured. Data on 30-day and 90-day outcomes is also requested. For more information on the CCC19 as well as a full list of participating institutions, visit: https://ccc19.org/.
NIHR Global Health Research Unit on Global Surgery – CovidSurg Cancer
This registry is available to any hospital performing elective cancer surgery. Investigators can enrol patients with confirmed diagnoses of colorectal, oesophagogastric, head and neck, lung, hepatopancreataobiliary, urological, neurological, gynaecological, breast cancers and soft-tissue or bone sarcoma. Inclusion criteria include patients that have surgery completed during the COVID-19 pandemic and patients that would have been planned for curative surgery in the pre-COVID-era that have surgery delayed or canceled during the COVID-19 pandemic. Please visit http://globalsurg.org/cancercovidsurg/.
NCI COVID-19 in Cancer Patients Study (NCCAPS)
NCCAPS is open to adults who are undergoing a test for SARS CoV-2 or have tested positive for SARS CoV-2 within the last two weeks and are undergoing active cancer treatment. There are plans to expand the trial soon to include children with cancer and COVID-19. NCCAPS is available to all National Clinical Trials Network (NCTN), NCI Community Oncology Research Program (NCORP) and NCI Experimental Therapeutics Clinical Trials Network (ETCTN) sites in the United States via the Cancer Trials Support Unit (CTSU). The study will be available to Canadian sites in the near future. Please note, per-case accrual reimbursement to participating sites will be provided by the NCTN or NCORP Group or ETCTN LAO credited with the enrollment. They hope to enroll patients at more than 1,000 sites and encourage your site to participate in this important study. All protocol documents can be found on the CTSU in the NCI protocol folder, protocol #NCICOVID (login required).